Skip to content

Effects of a Dietary Fibre Supplementation of a Low Calorie Diet on Appetite and Body Weight

A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a High Viscosity Dietary Fibre (PGX) Supplementation of a Low Calorie Diet on Appetite and Body Weight, in Overweight and Moderately Obese Females

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01109199
Enrollment
20
Registered
2010-04-23
Start date
2010-08-31
Completion date
2011-04-30
Last updated
2015-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Appetite Suppression, Weight Loss

Keywords

viscous, fibre, polysaccharide, appetite, hunger, satiety, weight management

Brief summary

This 18 week, randomized, double blind, placebo controlled trial will examine the effects of thick dietary fibre (PGX) supplementation of a low calorie diet (LCD) on appetite, weight loss, body composition, and compliance in overweight and moderately obese female. The investigators believe that 15 grams/day PGX supplementation of a low calorie diet over a 14-weeks period will elicit a better appetite score (e.g. reduced hunger) compared to the rice flour supplementation of the LCD.

Interventions

DIETARY_SUPPLEMENTPolyGlycopleX (PGX)

The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.

DIETARY_SUPPLEMENTRice flour

The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.

Sponsors

University of British Columbia
CollaboratorOTHER
InovoBiologic Inc.
CollaboratorINDUSTRY
Canadian Center for Functional Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI 25 - 35 Kg/m2

Exclusion criteria

* Medications and supplements that affect appetite * Known diabetes * Contraindications to LCD * Any other medical, social or geographic condition, which, in the opinion of the investigator would not allow safe completion of the protocol.

Design outcomes

Primary

MeasureTime frame
The difference in appetite score assessed from appetite Visual Analog Scale18 weeks

Secondary

MeasureTime frame
Change in weight (kilograms)18 weeks
Change in percentage of body fat18 weeks

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026